{"title":"使用钪-44放射标记PSMA-617的治疗前剂量测定","authors":"E. Eppard","doi":"10.5772/INTECHOPEN.79157","DOIUrl":null,"url":null,"abstract":"In recent years, the positron emitter scandium-44 moved into the focus of research pro- viding favorable nuclide properties for an application in nuclear medicine. Radiolabeling of PSMA-617 with scandium-44 as diagnostic match for [ 177 Lu]Lu-PSMA-617 instead of gallium-68 would enable pre-therapeutic dosimetry in clinical setting. Due to the chemical similarities of scandium and lutetium, the in vitro and in vivo characteristics of [ 177 Lu]Lu-PSMA-617 are more similar to [ 44 Sc]Sc-PSMA-617 than to the 68 Ga-compounds [ 68 Ga]Ga-PSMA-617 or [ 68 Ga]Ga-PSMA-11. [ 44 Sc]Sc-PSMA-617 showed its potential in a clinical setting as a PET imaging agent of prostate cancer providing several advan- tages over gallium-68 labeled tracers. The longer half-life of the nuclide would allow, for example, an optimized patient management and treatment, long-term or late time point imaging as well as transportation to more distant PET centers. However, especially clinical applications like individual dosimetry or intraoperative applications are still under investigation.","PeriodicalId":20788,"journal":{"name":"Prostatectomy","volume":"57 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":"{\"title\":\"Pre-Therapeutic Dosimetry Employing Scandium-44 for Radiolabeling PSMA-617\",\"authors\":\"E. Eppard\",\"doi\":\"10.5772/INTECHOPEN.79157\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In recent years, the positron emitter scandium-44 moved into the focus of research pro- viding favorable nuclide properties for an application in nuclear medicine. Radiolabeling of PSMA-617 with scandium-44 as diagnostic match for [ 177 Lu]Lu-PSMA-617 instead of gallium-68 would enable pre-therapeutic dosimetry in clinical setting. Due to the chemical similarities of scandium and lutetium, the in vitro and in vivo characteristics of [ 177 Lu]Lu-PSMA-617 are more similar to [ 44 Sc]Sc-PSMA-617 than to the 68 Ga-compounds [ 68 Ga]Ga-PSMA-617 or [ 68 Ga]Ga-PSMA-11. [ 44 Sc]Sc-PSMA-617 showed its potential in a clinical setting as a PET imaging agent of prostate cancer providing several advan- tages over gallium-68 labeled tracers. The longer half-life of the nuclide would allow, for example, an optimized patient management and treatment, long-term or late time point imaging as well as transportation to more distant PET centers. However, especially clinical applications like individual dosimetry or intraoperative applications are still under investigation.\",\"PeriodicalId\":20788,\"journal\":{\"name\":\"Prostatectomy\",\"volume\":\"57 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-11-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Prostatectomy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5772/INTECHOPEN.79157\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostatectomy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5772/INTECHOPEN.79157","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Pre-Therapeutic Dosimetry Employing Scandium-44 for Radiolabeling PSMA-617
In recent years, the positron emitter scandium-44 moved into the focus of research pro- viding favorable nuclide properties for an application in nuclear medicine. Radiolabeling of PSMA-617 with scandium-44 as diagnostic match for [ 177 Lu]Lu-PSMA-617 instead of gallium-68 would enable pre-therapeutic dosimetry in clinical setting. Due to the chemical similarities of scandium and lutetium, the in vitro and in vivo characteristics of [ 177 Lu]Lu-PSMA-617 are more similar to [ 44 Sc]Sc-PSMA-617 than to the 68 Ga-compounds [ 68 Ga]Ga-PSMA-617 or [ 68 Ga]Ga-PSMA-11. [ 44 Sc]Sc-PSMA-617 showed its potential in a clinical setting as a PET imaging agent of prostate cancer providing several advan- tages over gallium-68 labeled tracers. The longer half-life of the nuclide would allow, for example, an optimized patient management and treatment, long-term or late time point imaging as well as transportation to more distant PET centers. However, especially clinical applications like individual dosimetry or intraoperative applications are still under investigation.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
